June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
5 citations
,
July 2003 in “Annals of the Rheumatic Diseases” An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.
Tridax procumbens may boost the immune system.
September 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.
4 citations
,
January 2014 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” Oral minipulse therapy effectively treated bullous lichen planus in a 35-year-old woman.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
49 citations
,
August 2022 in “Frontiers in Immunology” Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.
March 2025 in “International Journal of Dermatology” Baricitinib may help people with long-term alopecia areata.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
July 2005 in “SKINmed/Skinmed” BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
Azathioprine can cause severe hair loss and low white blood cell count in lupus patients.
15 citations
,
June 1964 in “Experimental Biology and Medicine” Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
April 2018 in “Journal of Investigative Dermatology” Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
18 citations
,
October 2019 in “European Journal of Dermatology” September 2010 in “Middle East Journal of Digestive Diseases” Skin issues and diarrhea can signal ulcerative colitis, needing further checks.
June 2025 in “British Journal of Dermatology” Denosumab may cause alopecia areata.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.